Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 5/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.43 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13858621 | 1.00 | KMT2A (0.52) | KMT2AL3MBTL1KDM1AMAOBPDE4B | |
| SCHEMBL15716485 | 1.00 | KMT2A (0.52) | KMT2AL3MBTL1KDM1AMAOBPDE4B | |
| SCHEMBL13858620 | 1.00 | KMT2A (0.52) | KMT2AL3MBTL1KDM1AMAOBPDE4B | |
| SCHEMBL2012023 | 0.93 | KMT2A (0.48) | KMT2AL3MBTL1KDM1AMAOBPDE4B | |
| SCHEMBL1986245 | 0.93 | KMT2A (0.48) | KMT2AL3MBTL1KDM1AMAOBPDE4B | |
| SCHEMBL13461272 | 0.90 | KMT2A (0.52) | KMT2AL3MBTL1KDM1AMAOBPDE4B | |
| SCHEMBL13434397 | 0.90 | KMT2A (0.52) | KMT2AL3MBTL1KDM1AMAOBPDE4B | |
| SCHEMBL23369466 | 0.90 | NTRK1 (0.49) | KMT2AL3MBTL1KDM1AMAOBPDE4B | |
| SCHEMBL21622314 | 0.90 | NTRK1 (0.49) | KMT2AL3MBTL1KDM1AMAOBPDE4B | |
| SCHEMBL28046375 | 0.90 | KMT2A (0.45) | KMT2AL3MBTL1KDM1AMAOBPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108329246-B | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TRKA kinase inhibitors | 阵列生物制药公司 | 2021-02-26 | — | — | CN | disclosed |
| US-10851080-B2 | Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds | ARRAY BIOPHARMA INC. (US) | 2020-12-01 | — | — | US | disclosed |
| CN-107857755-B | N-pyrrolidinyl, N' -pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TRKA kinase inhibitors | 阵列生物制药公司 | 2020-10-27 | — | — | CN | disclosed |
| EP-3409670-B1 | N-PYRROLIDINYL, N'-PYRAZOLYL- UREA COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-06-18 | — | — | US | disclosed |
| EP-3409670-A1 | N-PYRROLIDINYL, N'-PYRAZOLYL- UREA COMPOUNDS AS TRKA KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| US-20180334450-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-20180179182-A1 | METHODS OF TREATMENT USING PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS | ARRAY BIOPHARMA INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-9896435-B2 | N-pyrrolidinyl,N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9878997-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160297796-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297758-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160280682-A1 | N-PYRROLIDINYL,N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-9233979-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9226922-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9226922-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150166564-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | Array BioPharama Inc. (US) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297796-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | TK1, UACA, TYMP | KMT2A 4294/4885L3MBTL1 3496/4885KDM1A 2107/4885 |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | RET, TK1, DSTYK | KMT2A 3907/4885L3MBTL1 1984/4885KDM1A 1954/4885 |
| US-20180179182-A1 | METHODS OF TREATMENT USING PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS | RNMT, MTAP, GMPS | KMT2A 3460/4885L3MBTL1 366/4885KDM1A 3600/4885 |
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK10, MAP3K1 | KMT2A 3443/4885L3MBTL1 3234/4885KDM1A 2668/4885 |
| US-20150166564-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | RET, TK1, DSTYK | KMT2A 3907/4885L3MBTL1 1984/4885KDM1A 1954/4885 |
| US-20160297758-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | TK1, UACA, TYMP | KMT2A 4272/4885L3MBTL1 3504/4885KDM1A 2018/4885 |
| US-20180334450-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | RET, TK1, DSTYK | KMT2A 3907/4885L3MBTL1 1984/4885KDM1A 1954/4885 |
| US-20160280682-A1 | N-PYRROLIDINYL,N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | TK1, CNKSR1, EDNRA | KMT2A 4331/4885L3MBTL1 3640/4885KDM1A 2280/4885 |
| US-10851080-B2 | Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds | RNMT, MTAP, GMPS | KMT2A 3460/4885L3MBTL1 366/4885KDM1A 3600/4885 |
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAP3K20 | KMT2A 3123/4885L3MBTL1 4253/4885KDM1A 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.